Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia

Comprehensive Psychiatry

Volumn 53, Issue 1, 2012, Pages 107-115

  Liu Seifert, Hong ^a   Osuntokun, Olawale O ^a   Feldman, Peter D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DEPRESSION; DOUBLE BLIND PROCEDURE; HEINRICH QUALITY OF LIFE SCALE; HOSTILITY; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 82755194899     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2010.12.003     Document Type: Article

References (40)

1. Ascher-Svanum H., Faries D.E., Zhu B., Ernst F.R., Swartz M.S., and Swanson J.W. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care J Clin Psychiatry 67 3 2006 453 460
2. Ayuso-Gutiérrez J.L., and del Río Vega J.M. Factors influencing relapse in the long-term course of schizophrenia Schizophr Res 28 2-3 1997 199 206 (Pubitemid 28055667)
3. Morken G., Widen J.H., and Grawe R.W. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia BMC Psychiatry 8 2008 32
4. Lindenmayer J.P., Liu-Seifert H., Kulkarni P.M., Kinon B.J., Stauffer V., and Edwards S.E. Medication non-adherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response J Clin Psychiatry 70 7 2009 990 996
5. Cramer J.A., and Rosenheck R. Compliance with medication regimens for mental and physical disorders Psychiatr Serv 49 2 1998 196 201 (Pubitemid 28071427)
6. Novak-Grubic V., and Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder Eur Psychiatry 17 3 2002 148 154 (Pubitemid 34800021)
7. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., and Keet I.P. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 9618 2008 1085 1097 (Pubitemid 351418005)
8. Kinon B.J., Ascher-Svanum H., Adams D.H., and Chen L. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials J Clin Psychopharmacol 28 5 2008 544 549
9. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., and Perkins D.O. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 2005 1209 1223 (Pubitemid 41345943)
10. Kinon B.J., Liu-Seifert H., Adams D.H., and Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia J Clin Psychopharmacol 26 6 2006 632 637 (Pubitemid 44772741)
11. Ascher-Svanum H., Nyhhuis A.W., Faries D.E., Kinon B.J., Baker R.W., and Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia Schizophr Bull 34 6 2008 1163 1171
12. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., and Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia BMC Psychiatry 6 2006 8
13. Beasley C.M. Jr, Stauffer V.L., Liu-Seifert H., Taylor C.C., Dunayevich E., and Davis J.M. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis J Clin Psychopharmacol 27 3 2007 252 258
14. Kane J.M., Osuntokun O., Kryzhanovskaya L.A., Xu W., Stauffer V.L., and Watson S.B. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia J Clin Psychiatry 70 4 2009 572 581
15. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R., and Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge J Clin Psychiatry 65 3 2004 354 360
16. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 2 1987 261 276 (Pubitemid 18039085)
17. Kay S.R., Opler L.A., and Fiszbein A. Positive and negative syndrome scale (PANSS) user's manual 2000 Multi-Health Systems, Inc. North Tonawanda (NY)
18. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., and Beasley C. Jr Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J Clin Psychopharmacol 17 5 1997 407 418 (Pubitemid 27414397)
19. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., and Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning J Clin Psychopharmacol 26 5 2006 453 461 (Pubitemid 44401463)
20. Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., and Cavazzoni P. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia Am J Psychiatry 162 10 2005 1879 1887 (Pubitemid 41428617)
21. Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms J Clin Psychopharmacol 26 2 2006 157 162 (Pubitemid 43740339)
22. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-III) 1980 American Psychiatric Association Washington (DC)
23. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th ed. 1994 American Psychiatric Association Washington (DC)
24. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 4th ed., text revision 2000 American Psychiatric Association Washington, DC
25. World Medical Association Declaration of Helsinki: recommendations guiding medical doctors in biomedical research involving human subjects As adopted by the 18th General Assembly; Helsinki, Finland; June 1964; and amended by the 52nd General Assembly; Edinburgh, Scotland; October 2000
26. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy Br J Psychiatry 151 1987 145 151 (Pubitemid 17102086)
27. Lindenmayer J.P., Bernstein-Hyman R., and Grochowski S. A new five factor model of schizophrenia Psychiatr Q 65 4 1994 299 322
28. Davis J.M., and Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials J Clin Psychiatry 62 10 2001 757 771 (Pubitemid 33104662)
29. Heinrichs D.W., Hanlon T.E., and Carpenter W.T. Jr The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome Schizophr Bull 10 3 1984 388 398
30. Browne S., Clarke M., Gervin M., Waddington J.L., Larkin C., and O'Callaghan E. Determinants of quality of life at first presentation with schizophrenia Br J Psychiatry 176 2000 173 176 (Pubitemid 32734844)
31. Dossenbach M., Pecenak J., Szulc A., Irimia V., Anders M., and Logozar-Perkovic D. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study J Clin Psychiatry 69 12 2008 1901 1915
32. Ascher-Svanum H., Nyhuis A., Faries D.E., Heiler L., and Kinon B.J. Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophrenia Clin Schizophr Relat Psychoses 2 3 2008 226 234
33. Haro J.M., Novick D., Suarez D., and Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study J Psychiatr Res 43 3 2009 265 273
34. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs BMC Med 3 2005 21
35. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., and Lambert M. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia J Clin Psychiatry 68 1 2007 75 80 (Pubitemid 46220127)
36. Ascher-Svanum H., Nyhuis A.W., Stauffer V., Kinon B.J., Faries D.E., Phillips G.A., Schuh K., Awad A.G., Keefe R., and Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives Curr Med Res Opin 26 10 2010 2403 2410
37. Gharabawi G.M., Greenspan A., Rupnow M.F.T., Kosik-Gonzalez C., Bossie C.A., and Zhu Y. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial BMC Psychiatry 6 2006 45
38. Liu-Seifert H., Houston J.P., Adams D.H., and Kinon B.J. Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia J Clin Psychopharmacol 27 4 2007 392 394 (Pubitemid 47075511)
39. Puschner B., Born A., Giessler A., Helm H., Leese M., and Bindman J.P. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study J Nerv Ment Dis 194 10 2006 746 752 (Pubitemid 44581101)
40. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., and Rosenheck R.A. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic Am J Psychiatry 163 4 2006 611 622 (Pubitemid 44464570)